Dr. Joseph Bertino Pharm.D.
Independent Consultant, Bertino Consulting
Member of the Healthcare Council
Council Member Biography
Joseph Bertino, PharmD, is an Associate Professor of Pharmacology at Columbia University College of Physicians and Surgeons in New York. Through Bertino Consulting, he consults to the pharmaceutical industry in areas of infectious diseases, drug metabolism, and clinical pharmacology. Dr. Bertino's research interests are in vaccines, antimicrobial pharmacokinetics and pharmacodynamics, pharmacogenetics, and pharmacogenomics. His publications include work in the area of aminoglycoside pharmacokinetics, pharmacodynamics and toxicity, drug-drug interactions, vaccine pharmacology, and application of pharmacogenetics to the drug development process. Dr. Bertino has also served on the Food and Drug Administration's Anti-infective and Antiviral Advisory Committees and remains as a special government employee. He is a recipient of the American College of Clinical Pharmacology Distinguished Investigator Award and the American College of Clinical Pharmacy Clinical Practice award. (This is me - Update Profile)
Employment History
- 2007 - Unspecified
- Independent Consultant, Bertino Consulting
- 2005 - 2007
- Scientific Director in Drug Development Center, ORDWAY RESEARCH INSTITUTE INC
- 2005 - Unspecified
- Associate Professor of Pharmacology, Columbia University College of Physicians and Surgeons
- 1997 - 2005
- Associate Professor of Clinical Pharmacology, Columbia University
- 1982 - 2005
- Section Chief of Clinical Pharmacology, BASSETT, MARY IMOGENE HOSPITAL INC
GLG NewsSM Analyses by Joseph Bertino(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Gene Targeted Drug Therapy for Heart Failure
September 23, 2008
Gene Targeted Drug Therapy for Heart Failure | www.bio-medicine.org
-Another step towards invididualized medicine -Proves that old drugs can be reinvented for useful purposes -Advances pharmacogenetics forward
-
Astra-Zeneca and Abbott partner on promoting Crestor..should Pfizer beware?
August 15, 2008
Abbott signs deal to promote Crestor in U.S. | www.chicagotribune.com
-Crestor sold 2.8 billion dollars in sales in the recent year, will this partnership result in long term exponential growth? -What are the implications for Crestor with generic simvastatin and with Lipitor going generic in the next few years? -Is a combination product going to bolster Crestor sales?
-
The New PhRMA “Code on Interactions with Health Care Professionals”: What will it mean?
July 17, 2008
PhRMA “Code on Interactions with Health Care Professionals” | www.thepinksheet.com
-The new code will limit all gifts and meals to healthcare professionals, thus reducing pharmaceutical representative contact time. -Medical education programs will follow guidelines established by professional education groups -The guidelines do not go far enough for sales representative-healthcare professional interactions
-
Non-Inferiority Studies: What do the numbers mean, how does the FDA interpret them?
October 11, 2007
Efficacy of Iclaprim in Complicated Skin and Skin Structure Infections: Preliminary Results of ASSIST-1 | www.idsociety.org
A recent abstract for the 2007 Infectious Diseases Society of American (IDSA) meeting has generated some concern among financial analysts. This non-inferiority study on iclaprim versus linezolid for treatment of complicated skin and skin structure infections showed that “The 95% CI for treatment difference (ICL-LZD) in the PP population was -8.4, -1.0%.” Because the 95% CI did not reach or cross 0, many individuals fear that the FDA will hold up approval of this compound. 2007 Infectious Diseases Society of American (IDSA) Abstract: http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={1E0D62C0-A5C5-49E5-883B-C0A0DC4D4745}&SKey={713BCC51-9119-49CC-BE88-A6043DC73587}&MKey={2BC0388C-EE56-4FA2-A529-EC82E2C7362A}&AKey={456A1804-CC97-4677-BF53-D872148C9EF7}
-
Will all adults over 60 get this vaccine?
August 2, 2006
FDA approves Zostavax, Merck's new vaccine for preventing shingles in adults 60 and older | www.therapeuticsdaily.com
-First vaccine to prevent or reduce herpes zoster infection
-Zoster has some health implications
-Zoster has some important cost implications.
Leading institutions connect with Joseph Bertino through GLG
GLG Study Groups with Joseph Bertino(?)
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Psychiatrists | 1535 |
| Psychiatrists (US) | 1136 |
| Generic Drug Economic Experts | 766 |
GLG Live Meetings with Joseph Bertino(?)
Joseph Bertino has not participated in any GLG Live Meetings.